BioSpace News Archive

Trefoil Therapeutics today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2023 following the close of regular trading on Tuesday, May 2, 2023.

GlucoTrack, Inc. announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies targeting eIF4E, is presenting pre-clinical data today on the company’s advancing eIF4E program for breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, FL.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv).

Evolent Health, Inc. (NYSE: EVH) today announced it will release its first quarter 2023 financial results on Wednesday, May 3, 2023, after market close, with a conference call to follow at 5 p.m. ET.

Nkarta, Inc. (Nasdaq: NKTX) today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the 2023 American Association of Cancer Research (AACR) Annual Meeting.

Nektar Therapeutics announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as several cost reduction initiatives, which the company expects will significantly reduce future operating expenses and extend its cash runway into the middle of 2026.

Rakovina Therapeutics Inc. is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, April 19, 2023, at 1:10pm Eastern standard time.

EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology, George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension in patients with advanced chronic kidney disease, a large unmet need for safe, effective therapies, and the potential of one therapy, Ocedurenone, to address this need.